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Abstract
Objective: The aim of this study was to delineate the profile of extended donor lungs in comparison to ideal donor lungs and to analyse their
outcome. Particular attention was given to donor lungs with a low PaO2 (!250 mmHg) before harvesting or with multiple extended criteria.
Methods: Between 1993 and 2003, 148 patients (79 women, 69 men, mean age 39.9 years) underwent lung transplantation. Indications were
cystic fibrosis in 35.8%, emphysema in 26.4%, pulmonary fibrosis in 12.2%, pulmonary hypertension in 9.5%, and others in 16.1%. Donor data and
recipients medical files were reviewed. Criteria for donor lungs were considered extended if one or more of the following criteria were met: age
O55 years, smoking O20 pack-years, PaO2 before harvesting !300 mmHg, pathologic chest X-ray, and purulent secretion at bronchoscopy. A
comparison between recipients from ideal and from extended donor lungs was performed with respect to the median duration of mechanical
ventilation, the median length of stay at the intensive care unit, postoperative complications, the 30-day and the 1-year survival, and the 6-
month follow-up spirometry. Results: Sixty-three (42.6%) donor lungs were considered extended and 20 (31.7%) met more than one criteria.
Outcome comparison between recipients from ideal (I) and extended (II) donor lungs did not statistically differ in postoperative complications
(18.8% (I) vs. 26.9% (II), PZ0.32), mean duration of mechanical ventilation (d) (4.4G2.7 (I) vs. 2.6G2.1 (II), PZ0.2), mean length of stay at the
ICU (d) (11.5G8.8 (I) vs. 9.2G6.9 (II), PZ0.4), 6-month pulmonary function (FEV1Z83G23% of the predicted value (I) vs. 82G18% (II), PZ
0.81), 30-day survival (90.6% (I) vs. 93.7% (II), PZ0.56), 1-year survival (83.5% (I) vs. 81% (II), PZ0.83). Thirty-day survival was also comparable
even in recipients from donor lungs with PaO2!250 mmHg (nZ8) (90.6% (I) vs. 87.5%, PZ0.57). The number of extended criteria had no impact
on the outcome. The combination of PaO2!300 mmHg with purulent secretion at bronchoscopy seemed to influence the early outcome of
recipients from extended donor lungs negatively. Conclusions: Our results suggest that the use of selected extended donor lungs does not
compromise the outcome after transplantation. PaO2 !250 mmHg before harvesting of the lungs is not an absolute contra-indication for
transplantation.
q 2005 Elsevier B.V. All rights reserved.
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Lung transplantation is an established treatment for
selected patients with end-stage lung or pulmonary vascular
disease [1,2]. Like for all solid-organ transplants, the
demand for donor lungs clearly exceeds the supply and the
mortality while waiting for transplantation remains high.
The donor lungs can become injured by the mechanism of
death, smoking, fluid resuscitation, neurogenic pulmonary1010-7940/$ - see front matter q 2005 Elsevier B.V. All rights reserved.
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One approach to increase the number of donor lungs is to
attempt to improve the condition of donor initially con-
sidered unacceptable by aggressive medical management
[1–4]. Additionally to overcome the limitation of donor
lungs, liberalization of donor selection criteria has been
considered to expand the available donor pool [5,6].
Previous reports from some experienced transplantation
centers worldwide suggest that the use of non-ideal or
extended (or marginal) donor lungs can expand the donor
pool without compromising results from transplantation
[2,3,5,7,8]. However, an increased early mortality rate in
transplanted patients was observed in some series after use
of extended donor lungs [3]. The aim of this retrospective
study was to delineate the profile of extended donor lungs
and to analyse the outcome after their use in ourEuropean Journal of Cardio-thoracic Surgery 27 (2005) 762–767www.elsevier.com/locate/ejcts
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donor lungs with a low PaO2 (!250 mmHg) before harvesting
or with multiple extended criteria.
Since lung transplantation has evolved during the last
years, consecutively to changes in donor lungs treatment
and in intraoperative and postoperative recipient manage-
ment, two periods of time were considered in the analysis
of the outcome, from 1993 to 1998 and from 1999 to
2003.0
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Fig. 1. Relation between the use of extended donor lungs and the 30-day
mortality from 1992 to 2003.2. Material and methods
From November 1992 to November 2003, a consecutive
series of 148 patients, including 79 women and 69 men, with
a mean age of 39.9 years (range 12–66 years) underwent lung
transplantation at the University Hospital Zurich. A total of
148 donors were used in this series. A retrospective analysis
of the computerized database was considered to review data
for this study. Indications for transplantation were cystic
fibrosis in 53 patients (35.8%), emphysema in 39 patients
(26.4%), pulmonary fibrosis in 18 patients (12.2%), pulmonary
hypertension in 14 patients (9.5%), and others like histiocy-
tosis, bronchiectasis, or lymphangio-leiomyomatosis in
24 patients (16.1%). Donors were divided in two groups:
ideal or extended. Donor lungs were considered extended if
any one of the following criteria were met: age O55 years,
smoking history O20 pack-years, pathologic chest X-ray,
PaO2 before harvesting of !300 mmHg on 100% oxygen with
5 cm H2O positive end-expiratory pressure, or purulent
secretion at bronchoscopy. Donor arterial PO2 was based on
the final measurement before harvesting and after donor
resuscitation and management. All the donors were managed
to maintain euvolemia and to avoid excessive fluid admin-
istration. Donors received 1 g of intravenous methylpredni-
solone (Solumedrolw) and 2.2 g amoxycillin with clavulanic
acid (Augmentinw) after initial contact with the donor
hospital. Harvesting of the lungs followed standard pro-
cedures with an antegrade flush through the main pulmonary
artery with the Euro-Collins solution till 1998 and then with a
low potassium dextran solution (Perfadexw) after adminis-
tration of prostaglandin E2 (Prostinw). A retrograde perfusion
was also done on the back table.
A subgroup analysis was performed comparing recipients
from ideal donor lungs with recipients from extended donor
lungs which met just one or more than one criteria, or with
PaO2 before harvesting !250 mmHg.
The analysed end-points consisted of the 30-day mor-
tality, the 1-year mortality, the 6-month follow-up spiro-
metry (forced expiratory volume in 1 s, FEV1), the median
duration of mechanical ventilation, the median length of
stay at the intensive care unit (ICU), and postoperative
complications.
Statistical analysis was performed with SPSS computer
soft-ware. The Student’s t-test for unpaired observation was
used where appropriate. Survival data were estimated by use
of the Kaplan–Meier life table analysis and compared
with the log rank test. Statistical significance was accepted
at P!0.05.3. Results
From the 148 patients included in the study, 63 (42.6%)
donor lungs were considered extended and 85 (57.4%) were
ideal donor lungs. The use of extended donor lungs increased
with time from 1999 up to 70% in 2003 (Fig. 1). The
indications for transplantation in the recipients of the ideal
donor group were cystic fibrosis in 31 patients (36.5%),
emphysema in 23 patients (27.1%), pulmonary fibrosis in 10
patients (11.8%), pulmonary hypertension in six patients
(7.1%), and others in 15 patients (17.5%). Twenty of the 63
recipients from extended donor lungs (31.7%) met more than
one criteria. The incidence of the different criteria defining
extended donor lungs was 12/63 (19%) for donor age O55
years, 20/63 (32%) for smoking O20 pack-years, 15/63 (24%)
for PaO2 before harvesting !300 mmHg, 29/63 (46%) for
pathologic chest X-ray, and 14/63 (22%) for purulent
secretion at bronchoscopy. Pathologic signs on chest X-ray
were often multiple and included infiltration in 15 patients,
pleural effusion and signs of contusion in six patients each,
atelectasis in five patients, and pneumothorax in one
patient.
Comparison of ideal donors and extended donors with
respect to donor cause of death, total donor lung ischemic
time, and donor intubation time showed no statistically
significant differences. However, donors were significantly
older in the extended donor group than in the ideal donor
group and donor gender was also significantly different with
a larger proportion of men in the ideal donor group than in
the extended donor group (Table 1). The type of procedure
(unilateral vs. bilateral) and the use of extracorporeal
circulation was comparable in the two groups (Table 1).
The incidence of postoperative complications, the recipient
duration of mechanical ventilation (d) as well as the length
of stay at the ICU (d) was also not significantly different
(Table 1). Postoperative complications included haema-
tothorax in nine patients, multiloculated pleural effusion in
seven patients, pneumonia in six patients, severe arrhythmia
in four patients, herniation of the lung in three patients,
residual pneumothorax and wound dehiscence in two
patients each. Haematothorax, multiloculated effusion was
treated thoracoscopically and recovery was uneventful. In
our series, eight patients (5.4%) were on intermittent
positive pressure ventilation (IPPV) when the transplantation
Table 1
Comparison between the two groups of ideal and extended donor lungs
according to the donor variables, the characteristics of the procedure, the
morbidity, the duration of mechanical ventilation and the length of stay at
the ICU
Ideal donor
group (nZ85)
Extended donor
group (nZ63)
P value
Donor parameters
Age (meanGSD) 32.0G11.6 39.4G13.8 0.001
Gender
Male 55 (64.7%) 14 (22.2%) 0.0001
Female 30 (35.3%) 49 (77.8%)
Cause of death
Trauma 43 (50.6%) 33 (50.8%) 0.087
Nontraumatic 42 (49.4%) 30 (49.2%)
Intubation time (h) 40G34 42G35 0.73
Ischemic time (h) 4.56G1.14 4.75G1.52 0.57
Recipients parameters
Type of transplantation
Unilateral 17 (20%) 9 (14.3%) 0.39
Bilateral 68 (80%) 54 (85.7%)
Extracorporeal circula-
tion
12 (14.1%) 12 (19.0%) 0.50
Postoperative compli-
cations
16 (18.8%) 17 (26.9%) 0.32
Duration of mechanical
ventilation (d)
4.4G2.7 2.6G2.1 0.20
Stay at the ICU (d) 11.5G8.8 9.2G6.9 0.40
Table 2
Thirty-day and 1-year survival in recipients from ideal donor lungs, from
extended donor lung according to the period of time
All patients Ideal donors Extended donors
30-day survival
1993–2003 91.9% (136/148) 90.6% (77/85) 93.7% (59/63)
1993–1998 87.5% (63/72) 85.4% (41/48) 91.7% (22/24)
1999–2003 96.1% (73/76) 97.3% (36/37) 94.9% (37/39)
1-year survival
1993–2003 82.4% (122/148) 83.5% (71/85) 81% (51/63)
1993–1998 77.8% (56/72) 79.2% (38/48) 75% (18/24)
1999–2003 86.8% (66/76) 89.2% (33/37) 84.7% (33/39)
Fisher’s exact test
P
Period 1993–1998 vs. period 1999–2003
30-day all patients 0.07
30-day ideal donors 0.13
30-day extended donors 0.63
1-year all patients 0.20
1-year ideal donors 0.25
1-year extended donors 0.51
Group ideal donors vs. group extended donors
30-day period 1993–1998 0.71
30-day period 1999–2003 1
1-year period 1993–1998 0.77
1-year period 1999–2003 0.74
Table 3
Mortality at 30 days according to the underlying disease and to the type of
donor lungs
Disease (n) 30-day mortality
Ideal Extended Total
Cystic fibrosis
(53)
2/31 (6.4%) 2/22 (9.1%) 4/53 (7.5%)
Emphysema (39) 1/23 (4.3%) 1/16 (6.2%) 2/39 (5.1%)
Pulmonary
fibrosis (18)
2/10 (20%) 0/8 2/18 (11.1%)
Pulmonary
hypertension
(14)
3/6 (50%) 1/8 (12.5%) 4/14 (28.6%)
Other (24) 0/15 0/9 0/24
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lungs were transplanted. One year after transplantation, five
patients were alive, including two recipients from ideal
donor lungs (66.6%) and three recipients from extended
donor lungs (60%).
In the 63 patients who received extended donor lungs, 22
(34%) had cystic fibrosis, 16 (25.4%) suffered from emphy-
sema, eight (12.7%) had a lung fibrosis and a pulmonary
hypertension each, and nine (14.3%) another underlying
disease. Extended donor lungs which met only one criterion
were observed in 37.2% in patients with cystic fibrosis, 18.6%
in patients with emphysema, 14% in patients with pulmonary
fibrosis, 14% in patients with pulmonary hypertension, and
16.2% in patients with another disease in comparison to 30,
40, 10, 10, and 10% for extended donor lungs which met more
than one criterion. Spirometry at 6 months was similar in
both groups of recipients, with FEV1Z83G23% of the
predicted value in the recipients from ideal donor lungs
and FEV1Z82G18% of the predicted value in the recipients
from extended donor lungs (PZ0.81).
After a mean follow-up of 3.3 years, the survival analysis
at 30 days and at 1 year after transplantation showed an
overall survival of 91.9% at 30 days and 82.4% at 1 year for
the 148 patients. No statistical significant difference was
observed between the two groups. Thirty-day survival was
90.6% in recipients from ideal donor lungs as compared to
93.7% in recipients from extended donor lungs (PZ0.56).
Furthermore, the survival at 1 year was also comparable
(83.5% in the group ideal donor vs. 81% in the group extended
donor lungs, PZ0.83). Comparison of 30-day and 1-year
survival between the periods 1993–1998 and 1999–2003 in all
patients, in recipients from ideal and from extended donor
lungs showed no statistical significant difference. Addition-
ally, the outcome of recipients from extended donors was
comparable to this of recipients from ideal donors for eachperiod of time (Table 2). The analysis of the survival
according to the number of criteria met to define extended
donor lungs revealed no significant difference between the
group with only one criterion and the group with multiple
criteria (93 and 95% at 30 days and 79.1 and 85% at 1 year)
(PZ1). The survival analysis according to the underlying
cause of the disease and according to the type of donor lung
is given in Tables 3 and 4. The mortality was higher in
patients with pulmonary hypertension at 30 days and at 1
year after transplantation but no increase of the 30-day
mortality was seen in the recipients from extended donor
lungs independently of the underlying disease. Although the
proportion of extended donor lungs increased with time, no
increase of the 30-day mortality was observed (Fig. 1).
The analysis of the criteria defining extended donor lungs
in the 12 recipients who receive such lungs and who died at
30 days or at 1 year showed age O50 years in one patient,
smoking O20 pack-years in four patients, PaO2 !300 mmHg
in four patients, pathologic chest X-ray in five patients, and
purulent secretion in three patients. If we correlate these
results with the incidence of the extended criteria in the 63
Table 4
Mortality at 1 year according to the underlying disease and to the type of
donor lungs
Disease (n) 1 year mortality
Ideal Extended Total
Cystic fibrosis (53) 3/31 (9.7%) 5/22 (22.7%) 8/53 (15.1%)
Emphysema (39) 2/23 (8.7%) 5/16 (31.2%) 7/39 (17.9%)
Pulmonary fibrosis (18) 3/10 (30%) 0/8 3/18 (16.7%)
Pulmonary hypertension (14) 4/6 (66.7%) 2/8 (25%) 6/14 (42.9%)
Other (24) 2/15 (13.3%) 0/9 2/24 (8.3%)
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each criterion to be associated with a bad outcome at
30 days or at 1 year was 4/15 (26.7%) for PaO2!300 mmHg,
3/14 (21.4%) for purulent secretion, 4/20 (20%) for smoking
O20 pack-years, 5/29 (17.2%) for pathologic X-ray, and 1/12
(8.3%) for age O55 years. All the patients who died at
30 days had one or more of the criteria PaO2!300 mmHg,
pathologic chest X-ray, or purulent secretion. In these
patients, the criteria age O55 years and smoking O20
pack-years were never met.
From the 15 patients who received extended donor lungs
with a PaO2 before harvesting !300 mmHg, special atten-
tion was given to the eight recipients from donor lungs with
PaO2!250 mmHg. The mean value of PaO2 was 208 mmHg
(range 168–237 mmHg). The recipients of these eight
extended donor lungs included two patients with cystic
fibrosis, three patients with emphysema, one patient with
pulmonary fibrosis, one patient with pulmonary hyperten-
sion, and one patient with histiocytosis. The 30-day survival
was 87.5%. The patient with pulmonary hypertension died
2 days after transplantation from an acute organ failure with
right heart insufficiency and failure following an important
reperfusion injury. The 1-year survival was 75% (6/8).
A second patient died 2 months after transplantation from
perforation of a duodenal diverticle. The survival at 30 days
and at 1 year in this special subgroup of patients was not
significantly different from that in the recipients from ideal
donor lungs and recipients from extended donor lungs.4. Discussion
The lack of donor lungs is still a relevant problem.
Selection criteria for suitable donors were defined at the
early days of lung transplantation but they have not been
evaluated in scientific trials [9–12]. In our study, we have
confirmed that satisfactory outcome of lung transplantation
can be achieved with the use of extended donor lungs.
Indeed, the use of extended donor lungs enabled us to
increase the number of lung transplants performed at our
institution, specially in the last 5 years without compromis-
ing early- and mid-term outcome.
Furthermore, there was no difference between recipients
from ideal donor lungs compared with extended donor lungs
in terms of duration of intubation, length of stay at the ICU,
6-month pulmonary function, and postoperative compli-
cations. Our rate of perioperative complications was
comparable in the two groups of recipients and corre-
sponded to the findings of other reports (15–25%) [3,5].Several lung transplant centers have also observed
successful transplantation with the use of extended donors
[2,3,5,7,8]. Aside a liberalization of donor selection criteria
to expand the available donor pool, another strategy to
increase the number of donor lungs includes attempts to
improve the condition of donors initially considered unac-
ceptable [1,2,13–15]. In our study, donor lungs were
considered extended in 42.6% after aggressive management
before harvesting. This corresponds to the results of other
centers in which up to 55% of recipients received extended
donor lungs [1,5,8]. Our approach to maximizing organ
utilization included early discussion with the intensivists at
the donor hospital, management of fluid balance, broncho-
scopic toilet of airways to remove secretion and reduce
atelectasis, antibiotics, initiation or increase of positive
end-expiratory pressure in an attempt to improve the gas
exchange. We also gave steroids routinely, since it has been
demonstrated that high-dose steroids after brain death can
improve oxygenation and can increase lung donor utilization
[15]. In our experience, we could observe no difference
between the ideal donors and the extended donors in terms
of cause of death and ischemic time. Indeed, it has been
suggested that brain injury may lead to upregulation of
proinflammatory cytokines with increase of the ischemia-
reperfusion injury [11]. Waller and coworkers demonstrated
that using donor lungs from patients who died of trauma did
not in itself compromise early graft outcome, provided that
appropriate management strategies were used, including
antibiotic treatment [16]. Our study corroborated this and
showed no difference between the outcome of recipients
from donors who died of trauma and those who died of
nontraumatic causes. According to the graft ischemic time,
several studies showed that ischemic time alone did not
increase 30-day or 1-year mortality [11,17]. However, the
combination of a cold ischemic time of O6 h with older
donor age seemed to increase the mid-term mortality [17].
However, although the extended donors were significantly
older in our study, no difference was seen in the analysis of
survival between the two groups.
The majority (46%) of our extended donors were defined
as such because of a pathologic chest X-ray. This was also the
case in the other published series [1,3,7,8]. However, the
relevance of the radiologic findings given by the transplan-
tation coordinator is often to take with caution and to be
interpreted with the bronchoscopic findings, the gas analysis
and the macroscopic aspect and the palpation of the lungs
before harvesting. In this respect, the experience of the
retrieval surgeon is very important, specially in the case of
lung contusion to decide if the whole lung or just a lobe can
be transplanted.
The majority of the patients transplanted at our
institution suffered from cystic fibrosis and not from
emphysema. This is probably due to the fact that our centre
is one of the leading centres in Europe in which lung volume
reduction surgery (LVRS) is performed. At the beginning of
our transplantation program, we have usually performed
unilateral transplantations in patients with emphysema. As
soon as LVRS became an established therapy in selected
patients with terminal emphysema, the number of emphy-
sematous patients who underwent transplantation
decreased [18].
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recipients from extended donor lungs did not differ from
the distribution in the whole series of 148 transplanted
patients. This similar repartition rules out the possible bias by
which extended donor lungs might have been reserved for
patients with a prognostic more favorable underlying disease
like cystic fibrosis or emphysema. This is an important remark
because the Washington University group suggested in their
publication in 1995 to use primarily extended donor lungs in
recipients with emphysema [8]. We have demonstrated the
possibility to use these lungs in selected patients with other
underlying diseases without compromising the results.
However, for patients with pulmonary hypertension, we
never used donor lungs, which had any form of a chest trauma
or any risk of other dysfunction. The only exception was made
for donors who rapidly developed neurogenic edema.
We were specifically concerned about whether any of the
extended donor criteria may predispose to a worse outcome.
Our study is the first report showing that the use of extended
donor lungs with a PaO2 !250 mmHg in selected cases is not
necessary associated with an unfavorable outcome. If the
measure of PaO2 remained low despite aggressive clinical
management in a donor with secretion and pathologic chest
X-ray, we generally did not use the donor lungs. On the other
hand, if the value of PaO2 showed a tendency to improve or
at least to stabilize after bronchoscopy or fluid balance
management, we generally used the donor lungs even if the
value before harvesting remained !250 mmHg in selected
cases, according to the judgment and experience of the
surgeon, but also according to the underlying disease of the
recipient. Specially in case of neurogenic edema, we
observed rapid recovery in all patients after transplantation.
The analysis of the criteria defining extended donor lungs
in the 12 recipients who receive such lungs and who died at
30 days or at 1 year showed that donors with an association
of PaO2!300 mmHg and purulent secretions should be used
with extreme caution, since these extended criteria might
influence the early outcome negatively. Extended donor age
and smoking history do not seem to affect early outcome but
may play a role in the mid-outcome. In our study, the early
mortality rate at 30 days was 6.3% in the recipients from
extended donor lungs and no difference was found between
the group with one criterion and the group with more than
one criterion. This rate was comparable to the mortality rate
in the ideal donor lungs group and also similar to the results
of previous reports [7,8]. However, in his series with 128
transplants, Pierre observed a 30-day mortality significantly
higher in the recipients of the extended donors (17.5 vs. 6.2%
in the recipients from ideal donors). A possible explanation
was a prolonged intubation time of the donors in the group
extended donor lungs with a greater risk for pneumonia and
fluid overload which was not the case in our series [3,5,19].
The outcome of lung transplanted patients has changed
during the last years. Our results confirmed this, showing a
trend to improvement of survival from 87.5 to 96.1% at 30
days and from 78.8 to 86.8% at 1 year after transplantation
between the periods 1993–1998 and 1999–2003. This change in
survival was observed in both groups of recipients from ideal
as well as from extended lung donors but was not statistical
significant. Several factors have contributed to this improve-
ment, including a more aggressive treatment of the donorlungs before harvesting, but also the development of a more
appropriate management intraoperative and at the intensive
care unit. The role of the preservation solution is difficult to
define. Although extensive laboratory experience and some
clinical studies suggest that low potassium dextran lung
preservation solution (Perfadex) is superior to Euro-Collins
solution, further studies are required to investigate the
impact of Perfadex in the mid- and long-term outcome of lung
transplantation. In a retrospective study, Dark et al. did not
find any difference in the mean ventilation time, the mean
intensive therapy unit stay, the mortality rate caused by
primary organ failure between Perfadex and Euro-Collins
solution [20]. Furthermore, in our experience, the outcome
of the recipients from extended donor lungs was comparable
to the outcome of the recipients from ideal donor lungs
before using the Perfadex preservation solution during the
period 1993–1998, which can probably rule out a significant
effect of Perfadex in the outcome.
In conclusion, our results demonstrate that the liberal use
of selected extended donor lungs does not compromise the
outcome after transplantation as long as the function
impairment is considered to be reversible within the first
days after transplantation, based on the overall clinical
judgment (e.g. minor thoracic trauma, secretion, neuro-
genic edema). Furthermore, PaO2 !250 mmHg before
harvesting of the lungs is not an absolute contra-indication
for transplantation. However, large experience is required in
the management of donor lungs before harvesting and their
selection results from an interactive process between the
transplant surgeon and the managing team of the donor. The
different parameters and findings have to be interpreted in a
dynamic way, in a context and not as single observations,
particularly with respect to chest X-ray and bronchoscopic
findings.
Our positive experience with extended donor lungs
emphasizes that the criteria generally admitted to define
an ideal donor lung are guidelines only.References
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2003;75:990–5.Appendix A. Conference discussion
Dr P. Filosso (Torino, Italy): We have the same results, but with a lower
number of lung transplantations performed at our Institution, in Torino, Italy.
I have two short questions for you.First: in our experience, we observe a high percentage of acute rejection
in patients receiving lung from a marginal donor.
Second: what is your policy in antibiotic treatment of recipients receiving
lungs with purulent secretions?
Dr Lardinois: First question: All the patients of our series received
induction therapy and an immunsuppression regimen based on steroids,
cyclosporine, and azathioprine or MMF. With this regimen, the rate of acute
rejection is very low. I am not able to give you the exact data, but we do not
see more acute rejections in recipients from extended donor lungs than in
recipients from ideal donor lungs.
Second question: All the patients who undergo lung transplantation at our
institution receive broad spectrum antibiotics initiated according to the
underlying disease and on the basis of the organisms isolated from the
different specimens before transplantation. The treatment can be changed or
adapted according to the additional information given by the analyse of the
bronchial secretion from donor lungs assessed during the transplantation.
Furthermore, the management of the donor lungs is very important,
particularly in case of purulent secretion. The systematic administration of
broad spectrum antibiotics combined with bronchoscopic toilet of airways to
remove secretion and reduce atelectasis is routinely performed. Antibiotic
therapy will be prolonged during weeks after transplantation.
Dr B. Koul (Lund, Sweden): My question is that in both the groups,
extended and nonextended groups, you had about 80% patients receiving the
double lungs, bilateral lung transplants, although the number of emphysema
was 30% in both the groups. Do you think by giving an extended donor lung that
bilateral transplant has to do with the bad results?
Dr Lardinois: At our institution, single-lung transplantations have been
performed at the beginning of our transplantation program. However, the
functional results are better after bilateral transplantation. Additionally,
published data suggest a lesser incidence of bronchiolitis obliterans after
bilateral procedure. Since 1998, we usually perform bilateral lung transplan-
tation, also because the majority of our recipients are CF patients who require
bilateral transplantation. Single-lung transplantation is an exception pro-
cedure in patients with emphysema for example when the other lung was
damaged or contused. To answer your question, we have not observed any
significant difference in the outcome of the recipients from extended donor
lungs between the two periods 1993–1998 and 1999–2003 and also between
recipients from extended and from ideal donor lungs after bilateral
procedure.
Dr E. Yildirim (Ankara, Turkey): As you have shown in one of your slides,
the duration of mechanical ventilation is short in the extended donor group. I
think it’s expected to be the opposite. Would you comment on it.
Dr Lardinois: Our results demonstrate that with a good strategy in
selecting the extended donor lungs and with an aggressive management of the
donor lungs, it is possible to use such lungs without compromising the early
postoperative phase, particularly the duration of intubation on the intensive
care unit.
